Format

Send to

Choose Destination
BJU Int. 2016 Dec;118(6):880-884. doi: 10.1111/bju.13483. Epub 2016 Apr 6.

Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare.

Author information

1
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
2
Division of Urology, Harasanshin Hospital, Fukuoka, Japan.

Abstract

OBJECTIVE:

To investigate the potential relationship of steroid usage with prostate-specific antigen (PSA) flare as well as the prognostic impact of PSA flare, which is known to occur in 10-20% of patients with metastatic castration-resistant prostate cancer during docetaxel chemotherapy.

PATIENTS AND METHODS:

This study included 71 patients with metastatic castration-resistant prostate cancer treated by docetaxel chemotherapy with co-introduction of a steroid. PSA flare was defined as a transient PSA increase followed by a PSA decrease.

RESULTS:

PSA flare was recognized in 7.0-23.9% of patients according to the definition used. Intriguingly, men with steroid intake before the initiation of docetaxel chemotherapy experienced significantly fewer PSA flares. The progression-free survival rate in men with PSA flare was equivalent to that of PSA responders, but significantly better than men with PSA failure.

CONCLUSIONS:

Our results suggest that de novo steroid co-introduction with docetaxel chemotherapy induces the PSA flare phenomenon. This novel finding may account for the mechanism of PSA flare as well as being valuable for distinguishing PSA elevation attributable to PSA flare from that attributable to PSA failure.

KEYWORDS:

androgen receptor; docetaxel; mutation; prostate cancer; prostate-specific antigen flare

Comment in

PMID:
26991851
DOI:
10.1111/bju.13483
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center